Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 45 - Medicinal preparations containing active ingredients not provided for in groups
Patents for A61K 45 - Medicinal preparations containing active ingredients not provided for in groups (115,020)
12/1996
12/10/1996US5583156 An oxycarboxylic compound
12/10/1996US5583153 Administering taxol solubilized in carrier to suppress symptoms of progressive inflammatory autoimmune arthritis in mammals
12/10/1996US5583128 Contraception in female primates without affecting the menstrual cycle
12/10/1996US5583117 Acylated uridine and cytidine for elevating tissue uridine and cytidine
12/10/1996US5583101 S-nitroso amino acids
12/10/1996US5582862 Administering to treat myocardial infarction or blood clot
12/10/1996US5582172 Intravascular administering a particle carrier comprising an organic inner core surface grafted with carbohydrates specific bonding to lymph nodes
12/10/1996CA2082270C Anti-viral therapy
12/10/1996CA1338779C Method for treating pain associated with herpes-zoster and post-herpetic neuralgia by topical application of local anesthetics
12/05/1996WO1996038558A2 A human purinergic p2u receptor
12/05/1996WO1996038557A1 Hepatocyte growth factor receptor antagonists and uses thereof
12/05/1996WO1996038548A1 Oxygen activatable formulations for disinfection or sterilization
12/05/1996WO1996038457A1 Methods for in vivo reduction of nitric oxide levels and compositions useful therefor
12/05/1996WO1996038426A1 Novel isoxazoline and isoxazole fibrinogen receptor antagonists
12/05/1996WO1996038183A1 Contrast medium and its use
12/05/1996WO1996038178A1 Allogeneic and xenogeneic transplantation
12/05/1996WO1996038172A1 Connective tissue growth factor
12/05/1996WO1996038168A1 Methods and uses of connective tissue growth factor as an induction agent
12/05/1996WO1996038167A1 Use of fibroblast growth factors to stimulate bone growth
12/05/1996WO1996038155A1 Method of treating disorders associated with cholinergic hypofunctionality
12/05/1996WO1996038148A1 Method for preventing intervention-associated stenosis following non-bypass, invasive interventions
12/05/1996WO1996038143A1 The use of alpha-1c-selective adrenoceptor agonists for the treatment of urinary incontinence
12/05/1996WO1996038140A1 Agents for use against parasitic protozoa
12/05/1996WO1996038136A1 Localized use of nitric oxide-adducts to prevent internal tissue damage
12/05/1996DE19519821A1 Mittel gegen parasitäre Protozoen Agents against parasitic protozoa
12/05/1996CA2223276A1 Methods for in vivo reduction of nitric oxide levels and compositions useful therefor
12/05/1996CA2222609A1 Methods and uses of connective tissue growth factor as an induction agent
12/05/1996CA2222573A1 The use of alpha-1c-selective adrenoceptor agonists for the treatment of urinary incontinence
12/05/1996CA2222429A1 Contrast medium and its use
12/05/1996CA2222147A1 Novel isoxazoline and isoxazole fibrinogen receptor antagonists
12/05/1996CA2220955A1 A novel human purinergic p2u receptor
12/05/1996CA2219452A1 Method for preventing intervention-associated stenosis following non-bypass invasive interventions
12/04/1996EP0745611A1 Interleukin-4 and Interleukin-1beta synergistically induce VCAM-1
12/04/1996EP0745383A2 An enteric preparation coated with a non-solvent enteric coating agent using a liquid plasticizer
12/04/1996EP0745136A1 B7-1-specific ligands, and their use for the induction of t cell anergy
12/04/1996EP0745124A1 Mammalian cell cycle protein
12/04/1996EP0744957A1 Composition and method for preventing and treating inflammation with immunoglobulin a
12/04/1996EP0744954A1 Cathepsin d is an amyloidogenic protease in alzheimer's disease
12/04/1996EP0744894A1 Self-assembling multimeric nucleic acid constructs
12/04/1996EP0547191B1 Particulate vector having selective tropism, method of preparation and pharmaceutical composition
12/04/1996EP0485486B1 Process for disinfecting musculoskeletal tissue and tissues prepared thereby
12/04/1996EP0479920B1 Novel antibodies reactive with human carcinomas
12/03/1996US5580984 Retroviral protease inhibiting compounds
12/03/1996US5580962 Purification of activated protein c by ion exchange chromatography to remove serum amyloid p, antibodies and thrombin-inhibitor complex, then inactivating viruses
12/03/1996US5580902 Applying ethyl pyruvate solutions to reduce facial wrinkling
12/03/1996US5580547 Pigmentation of mammalian skin
11/1996
11/28/1996WO1996037775A1 Methods for g protein coupled receptor activity screening
11/28/1996WO1996037619A1 Method for reproducing in vitro the rna-dependent rna polymerase and terminal nucleotidyl transferase activities encoded by hepatitis c virus (hcv)
11/28/1996WO1996037609A1 A gene switch comprising an ecdysone receptor
11/28/1996WO1996037230A1 Immunostimulating-wound healing compositions and methods for preparing and using same
11/28/1996WO1996037229A1 Antihistamine-wound healing compositions and methods for preparing and using same
11/28/1996WO1996037228A1 Antibacterial-wound healing compositions and methods for preparing and using same
11/28/1996WO1996037227A1 Dermatological-wound healing compositions and methods for preparing and using same
11/28/1996WO1996037226A2 Combinations for the treatment of parkinsonism containing selective nmda antagonists
11/28/1996WO1996037208A1 Allogeneic cell therapy for cancer following allogeneic stem cell transplantation
11/28/1996WO1996037203A1 Method to increase retinal blood flow
11/28/1996WO1996037201A2 METHODS AND COMPOSITIONS FOR INHIBITING 5α-REDUCTASE ACTIVITY
11/28/1996WO1996037199A1 Use of r-enantiomer of n-propargyl-1-aminoindan, salts, and compositions thereof
11/28/1996WO1996037192A1 Pharmaceutical and cosmetic compositions containing sphingo- and glycolipids
11/28/1996WO1996025931A3 Use of fused benzothiazoles as neuroprotectants
11/28/1996DE19514104A1 Beschichtung für in den Blutstrom oder in das Gewebe des menschlichen Körpers einbringbares Biomaterial Coating for can be introduced into the bloodstream or into the tissue of the human body biomaterial
11/28/1996CA2221458A1 Use of r-enantiomer of n-propargyl-1-aminoindan, salts, and compositions thereof
11/28/1996CA2221236A1 Methods and compositions for inhibiting 5.alpha.-reductase activity
11/28/1996CA2220971A1 Allogeneic cell therapy for cancer following allogeneic stem cell transplantation
11/28/1996CA2219121A1 A gene switch comprising an ecdysone receptor
11/28/1996CA2218726A1 Methods for g protein coupled receptor activity screening
11/28/1996CA2218539A1 Immunostimulating-wound healing compositions and methods for preparing and using same
11/27/1996EP0744177A2 Composition containing at least one essential oil and a provitamin, useful in the prevention and treatment of pressure sores
11/27/1996EP0743956A1 Pretargeting methods and compounds
11/27/1996EP0743858A1 Antioxidants and intracellular glutathione raising agents for therapeutic treatments
11/27/1996EP0743857A1 Method of making polymers having specific properties
11/27/1996EP0743853A1 Compounds active at a novel site on receptor-operated calcium channels useful for treatment of neurological disorders and diseases
11/27/1996EP0743852A1 Treatment of normotensive glaucoma with angiotensin ii antagonists
11/27/1996EP0494972B1 Effervescent dosage form and method of administering same
11/27/1996CN1136777A Immunomodulating compositions from bile
11/27/1996CN1136776A Oral formulations of antifungal
11/26/1996US5578644 Periodically applying isocitric acid or salt to face
11/26/1996US5578639 PLA2 inhibitors and their use for inhibition of intestinal cholesterol absorption
11/26/1996US5578611 Antitumor agents and prostate tumor detection by binding human alpha-adrenergic receptor and histamine h1 receptors
11/26/1996US5578590 Pharmaceutical composition preparation for use in inhibiting protein kinase C
11/26/1996US5578588 Nasal administration of a precursor
11/26/1996US5578576 Nutrient solution for reducing side effects of nonsteroidal antiinflammatory drugs
11/26/1996US5578572 Anti-gram-positive bacterial methods and materials
11/26/1996US5578571 Cytostatic or cytotoxic combination of active substances for use in therapeutic procedures
11/26/1996US5578320 Method of dehydrating liposomes using protective sugars
11/26/1996US5578287 Three-step pretargeting methods using improved biotin-active agent
11/21/1996WO1996036709A1 Transforming growth factor alpha hii
11/21/1996WO1996036698A1 Mch2, AN APOPTOTIC CYSTEINE PROTEASE, AND COMPOSITIONS FOR MAKING AND METHODS OF USING THE SAME
11/21/1996WO1996036696A1 Continuous selective clonogenic expansion of relatively undifferentiated cells
11/21/1996WO1996036360A1 Immunoconjugates comprising single-chain variable region fragments of anti-cd-19 antibodies
11/21/1996WO1996036334A1 Use of calcium intracellular store inactivators and formulations thereof as cell growth inhibitors
11/21/1996WO1996036327A1 Method of modulating microcirculation
11/21/1996WO1996036318A2 Three-phase pharmaceutical form with constant and controlled release of amorphous active ingredient for single daily application
11/21/1996WO1996036317A1 Production scale method of forming microparticles
11/21/1996WO1996029407A3 Cellubrevin homologs
11/21/1996CA2221623A1 Continuous selective clonogenic expansion of relatively undifferentiated cells
11/21/1996CA2218898A1 Immunoconjugates comprising single-chain variable region fragments of anti-cd19 antibodies
11/20/1996EP0743059A2 Process for applying antibacterial oral composition to dental implant areas
11/20/1996EP0742723A1 Homologous recombination for universal donor cells and chimeric mammalian hosts
11/20/1996EP0742722A1 Method for increasing bioavailability of oral pharmaceutical compositions
1 ... 1084 1085 1086 1087 1088 1089 1090 1091 1092 1093 1094 1095 1096 1097 1098 1099 1100 1101 1102 1103 1104 ... 1151